Data/hora: 12/06/2024 15:18:24

Provedor de dados: 	55	
País: 	Brazil	
Título: 	Acute pancreatitis associated with boceprevir: a case report	
Autores: 	Bilar,Juliana Miguel; Carvalho-Filho,Roberto José; Mota,Carolina Frade Magalhães Girardin Pimentel; Fucuta,Patricia da Silva; Ferraz,Maria Lucia Cardoso Gomes.	
Data: 	2014-08-01	
Ano: 	2014	
Palavras-chave: 	Hepatitis C; Protease inhibitor; Side effect.	
Resumo: 	Approximately 170 million people are infected with hepatitis C, and the sustained virological response rate to treatment with pegylated interferon and ribavirin is 30-50%. In an attempt to improve the chances of cure, boceprevir is being added to therapy, but it is associated with an increased incidence of adverse events. We herein report a case of acute pancreatitis developed during treatment with pegylated interferon, ribavirin and boceprevir. Boceprevir was the most likely cause of drug-associated pancreatitis after the most common causes were ruled out, since this adverse event had not occurred when the patient had previously been exposed to pegylated interferon and ribavirin and there was no recurrence of the episode of pancreatitis when these two drugs were reintroduced. Acute pancreatitis is a rare adverse event associated with boceprevir therapy, but a potentially fatal event. Sequential determination of pancreatic enzymes should be considered during hepatitis C treatment with boceprevir.	
Tipo: 	Info:eu-repo/semantics/report	
Idioma: 	Inglês	
Identificador: 	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702014000400454	
Editor: 	Brazilian Society of Infectious Diseases	
Relação: 	10.1016/j.bjid.2014.03.008	
Formato: 	text/html	
Fonte: 	Brazilian Journal of Infectious Diseases  v.18 n.4 2014	
Fonte: 	info:eu-repo/semantics/openAccess